Original contribution
The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery

https://doi.org/10.1016/0952-8180(96)00080-3Get rights and content

Abstract

Study Objective: To evaluate the efficacy of a 2 million KIU single dose of aprotinin on blood loss, transfusion requirements, and incidence of deep venous thrombosis (DVT) in patients undergoing total hip replacement surgery.

Design: Randomized study.

Setting: Operating theater at an orthopedic hospital.

Patients: 40 adult patients scheduled for total hip replacement surgery.

Interventions: Patients were randomized to two groups. Group A (n = 20) received 2 million KIU of aprotinin over 20 minutes, Group C (n = 20), the control group, received placebo. Anesthesia and surgical technique were standardized.

Measurements and Main Results: Intraoperative blood loss, postoperative blood loss, transfusion requirements (48 hr), hemoglobin, coagulation parameters, and platelet counts were assessed. On the seventh postoperative day, all patients in both groups underwent venography to ascertain the incidence of DVT. We found no significant difference in blood loss or transfusion requirements between the two groups. Intraoperative and postoperative blood losses, coagulation parameters, and incidence of DVT did not differ significantly between the two groups.

Conclusion: A single 2 million KIU bolus dose of aprotinin does not reduce perioperative blood loss or transfusion requirements. Aprotinin therapy, when used in conjunction with other antithrombotic therapies, does not increase the incidence of DVT after major orthopedic surgery.

References (18)

There are more references available in the full text version of this article.

Cited by (46)

  • Use of aprotinin to reduce blood loss and transfusion in major orthopedic surgery: A meta-analysis

    2014, Transfusion and Apheresis Science
    Citation Excerpt :

    A total of 1276 patients were enrolled in the randomized controlled trials. Nine studies involved hip surgery [11–19], three studies involved spinal surgery [20–22], two studies involved knee surgery [23,24] and four studies involved other surgery [25–28]. The number of patients included in these randomized controlled trials ranged from 17 to 352.

  • Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials

    2009, Thrombosis Research
    Citation Excerpt :

    Differences in surgical techniques and transfusion thresholds are likely to have contributed to the differences observed between studies. Lastly, estimating blood loss was variable, since blood due to hematomas [57] or tissue extravasation [77] were rarely measured and only 5[51,55,57,60,70] studies used a method to account for this source of blood loss. Few studies reported the type of surgical hemostasis (i.e., electrical cauterization, tissue adhesives) utilized; these techniques are known to reduce blood loss during surgery [70].

  • Transfusion avoidance in orthopedic surgery

    2004, Journal of Cardiothoracic and Vascular Anesthesia
View all citing articles on Scopus

Supported in part by a grant from the Cappagh Hospital Trust, Dublin, Ireland.

Registrar in Anaesthesia.

Consultant in Anaesthesia.

View full text